SCHEMBL7147217

SCHEMBL7147217

CN(C(=O)CNC=O)c1ccc(CO[Si](C)(C)C(C)(C)C)cc1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPIB P23284 2/20 0.35
BACE1 P56817 1/20 0.34
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
HSD17B10 Q99714 1/20 0.32
MLYCD O95822 2/20 0.31
RET P07949 2/20 0.31
NOTUM Q6P988 1/20 0.31
NR1H4 Q96RI1 1/20 0.30
ADRB1 P08588 1/20 0.30
TACR1 P25103 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7142708 0.86 PPIB (0.37) PPIBBACE1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL7148520 0.83 PPIB (0.38) PPIBALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL7151466 0.81 PPIB (0.43) PPIBALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL7141047 0.76 PPIB (0.40) PPIBMLYCD
SCHEMBL7135707 0.73 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2HPGDMLYCD
SCHEMBL5638853 0.72 PPIB (0.49) PPIBALDH1A1KDM4ESMN1; SMN2HTT
SCHEMBL8000219 0.69 SMN1; SMN2 (0.39) ALDH1A1KDM4ESMN1; SMN2NPC1GAA
SCHEMBL979052 0.69 BACE1 (0.40) BACE1ALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL19656353 0.69 AOC3 (0.32) BACE1
SCHEMBL19656340 0.68 TERT (0.32) PPIBBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP PPIB 304/4885BACE1 261/4885ALDH1A1 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.